Soligenix Inc (SNGX)
NASDAQ:SNGX
Top Page
Soligenix
(NASDAQ:SNGX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▲(4.17% Upside)
Action:ReiteratedDate:01/24/26
The score is held down primarily by very weak financial performance (no revenue, persistent losses, and ongoing cash burn). Technical indicators are neutral-to-soft with price below key moving averages and a negative MACD. Corporate events provide some support via regained Nasdaq compliance, but the new ATM facility underscores continued reliance on external financing, while valuation metrics are constrained by negative earnings and no dividend.
Positive Factors
ThermoVax vaccine stability platform
ThermoVax reduces cold-chain dependency, a structural advantage for vaccine distribution and biodefense programs. Heat-stable formulations can attract government funding and strategic partners, creating durable licensing and collaboration opportunities that persist beyond any single clinical readout.
Negative Factors
No revenue and persistent cash burn
Zero revenue and roughly −$8.4M operating free cash flow in 2024 show structural negative cash generation. Persistent operating losses force continual external financing, limit investment in commercialization, and make sustainability highly contingent on positive trial outcomes or milestone payments.
Read all positive and negative factors
Positive Factors
Negative Factors
ThermoVax vaccine stability platform
ThermoVax reduces cold-chain dependency, a structural advantage for vaccine distribution and biodefense programs. Heat-stable formulations can attract government funding and strategic partners, creating durable licensing and collaboration opportunities that persist beyond any single clinical readout.
Read all positive factors
Soligenix (SNGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.40M
Dividend YieldN/A
Average Volume (3M)129.00K
Price to Earnings (P/E)―
Beta (1Y)0.26
Revenue GrowthN/A
EPS Growth53.13%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.58
Shares Outstanding10,086,130
10 Day Avg. Volume128,132
30 Day Avg. Volume129,000
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.00
P/FCF Ratio-0.53
Enterprise Value/Market Cap0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.79K
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$10.00Price Target Upside594.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$800.00K
Soligenix Business Overview & Revenue Model
Company Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Spec...
How the Company Makes Money
Soligenix makes money primarily through the research, development, and commercialization of its biopharmaceutical products. The company's revenue streams include government grants and contracts, especially for its biodefense programs, as well as p...
Soligenix Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 250.00K | 33.35K | 1.93M |
| Gross Profit | -703.00 | -119.37K | -742.05K | -300.82K | -695.29K | 109.58K |
| EBITDA | -12.32M | -9.46M | -7.67M | -14.11M | -12.48M | -18.45M |
| Net Income | -11.46M | -8.27M | -6.14M | -13.80M | -12.55M | -17.69M |
Balance Sheet | ||||||
| Total Assets | 11.29M | 8.97M | 9.80M | 14.28M | 26.87M | 19.89M |
| Cash, Cash Equivalents and Short-Term Investments | 10.53M | 7.82M | 8.45M | 13.36M | 26.04M | 18.68M |
| Total Debt | 385.05K | 1.48M | 3.49M | 10.24M | 9.96M | 10.51M |
| Total Liabilities | 3.70M | 4.85M | 7.27M | 16.75M | 16.15M | 16.15M |
| Stockholders Equity | 7.60M | 4.12M | 2.52M | -2.47M | 10.72M | 3.74M |
Cash Flow | ||||||
| Free Cash Flow | -9.76M | -8.40M | -8.60M | -12.66M | -11.75M | -11.46M |
| Operating Cash Flow | -9.75M | -8.40M | -8.60M | -12.65M | -11.74M | -11.45M |
| Investing Cash Flow | -3.92K | 0.00 | 0.00 | -13.07K | -11.79K | -7.15K |
| Financing Cash Flow | 10.47M | 7.76M | 3.66M | 76.82K | 19.06M | 24.68M |
Soligenix Technical Analysis
Neutral
1.44
Price Trends
1.21
Negative
1.32
Negative
1.68
Negative
Market Momentum
<0.01
Negative
51.28
Neutral
35.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNGX, the sentiment is Neutral. The current price of 1.44 is above the 20-day moving average (MA) of 1.20, above the 50-day MA of 1.21, and below the 200-day MA of 1.68, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.28 is Neutral, neither overbought nor oversold. The STOCH value of 35.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SNGX.
Soligenix Risk Analysis
Soligenix disclosed 47 risk factors in its most recent earnings report. Soligenix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Soligenix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $10.82M | -3.82 | -22.03% | ― | -41.76% | 87.36% | |
47 Neutral | $9.71M | -1.35 | -119.35% | ― | 178.19% | 68.57% | |
46 Neutral | $3.11M | -0.38 | -489.66% | ― | 8.52% | 79.51% | |
43 Neutral | $11.40M | -0.50 | -267.10% | ― | ― | 53.13% | |
41 Neutral | $7.15M | -0.33 | ― | ― | ― | ― |
* Healthcare Sector Average
SNGX
Soligenix
1.13
-1.08
-48.87%
BLRX
Bioline RX Ltd Sponsored ADR
2.37
-0.68
-22.30%
CANF
Can-Fite BioPharma
3.14
-26.44
-89.38%
GOVX
GeoVax Labs
1.40
-26.35
-94.95%
AIMD
Ainos
1.39
-1.16
-45.49%
Soligenix Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Soligenix Establishes At-The-Market Equity Offering Program
Positive
Jan 23, 2026
On January 23, 2026, Soligenix, Inc. entered into an at-the-market issuance sales agreement with Rodman Renshaw, LLC, allowing the company, at its discretion, to sell up to $3.45 million of its common stock through Rodman as sales agent under an ...
Delistings and Listing ChangesRegulatory Filings and Compliance
Soligenix Regains Nasdaq Compliance as of November 2025
Positive
Nov 18, 2025
Soligenix, Inc. reported that on November 18, 2025, it received confirmation from Nasdaq that it had regained compliance with the minimum stockholders’ equity requirement necessary for continued listing on The Nasdaq Capital Market. This fol...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.